Effects of Stress on Ovarian Cancer, Other Cancer Types

Video

Susan Lutgendorf, PhD, professor, Department of Psychological and Brain Sciences, The University of Iowa, discusses a study investigating the effects of stress on immune response and tumor microenvironment in ovarian cancer and other cancer types.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
TAR-200 Shows Durable Response in BCG-Unresponsive NMIBC: SunRISe-1 Cohort 2
TAR-200 Shows Durable Response in BCG-Unresponsive NMIBC: SunRISe-1 Cohort 2
Predicting Cretostimogene Grenadenorepvec Response With Urinary Genomics
Predicting Cretostimogene Grenadenorepvec Response With Urinary Genomics
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Shouse Covers the Future of Lymphoma Therapy With Bispecific Antibodies
Shouse Covers the Future of Lymphoma Therapy With Bispecific Antibodies
42nd Annual Miami Breast Cancer Conference: The Show and After Show
42nd Annual Miami Breast Cancer Conference: The Show and After Show
Choosing Itacitinib for GVHD Prophylaxis: Insights From Popat
Choosing Itacitinib for GVHD Prophylaxis: Insights From Popat
Avelumab Maintenance in Advanced Urothelial Carcinoma: Key Insights
Avelumab Maintenance in Advanced Urothelial Carcinoma: Key Insights
Assessing the Need for Extended Monitoring After Axi-Cel Infusion
Assessing the Need for Extended Monitoring After Axi-Cel Infusion
Lenvatinib Plus Pembrolizumab Reinforces Long-Term Efficacy in Advanced RCC
Lenvatinib Plus Pembrolizumab Reinforces Long-Term Efficacy in Advanced RCC
Related Content
High CR Rate with Cretostimogene for BCG-Failed Bladder Cancer

High CR Rate with Cretostimogene for BCG-Failed Bladder Cancer

Ashley Chan
April 26th 2025
Article

Cretostimogene showed high and durable responses in heavily pretreated BCG-unresponsive NMIBC with CIS in a phase 3 trial. Well-tolerated with minimal high-grade TRAEs.

Read More

Advancing the Treatment of Cervical and Endometrial Cancers

Advancing the Treatment of Cervical and Endometrial Cancers

June 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Listen

AUA 2025: A Sneak Peek for Community Oncologists/Urologists

AUA 2025: A Sneak Peek for Community Oncologists/Urologists

Jordyn Sava
April 22nd 2025
Article

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in prostate cancer, and more.

Read More

Precision Medicine Guiding Ovarian Cancer Treatment

Precision Medicine Guiding Ovarian Cancer Treatment

July 15th 2020
Podcast

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Listen

ADC Development in Ovarian Cancer: What’s Next for FRα and Beyond?

ADC Development in Ovarian Cancer: What’s Next for FRα and Beyond?

Chris Ryan
April 5th 2025
Article

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer.

Read More

Relacorilant Extends Survival in Platinum-Resistant Ovarian Cancer

Relacorilant Extends Survival in Platinum-Resistant Ovarian Cancer

Jordyn Sava
March 31st 2025
Article

The combination of relacorilant and nab-paclitaxel improved progression-free and overall survival in patients with platinum-resistant ovarian cancer.

Read More